

## SEOK-GOO CHO, M.D., Ph.D.

<b>POSITION TITLE</b> Professor of Medicine (Hematology, Blood and Marrow Transplantation)			
<b>CONTACT INFORMATION</b> Seoul St. Mary's Hospital. College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 137-701, Republic of Korea Tel: +82-2-2258-6052,, Fax: +82-2-599-3589, E-mail: chosg@catholic.ac.kr			
<b>EDUCATION/TRAINING</b>			
<b>INSTITUTION AND LOCATION</b>	<b>DEGREE</b>	<b>YEAR(s)</b>	<b>FIELD OF STUDY</b>
The Catholic University of Korea, College of Medicine, Seoul, Korea	M.D.	1988	Medicine
The Catholic Catholic Graduate School of Medicine, Seoul, Korea	M.S.	1992	Internal Medicine
	Ph.D.	1998	Internal Medicine/Hematology
<b>CLINICAL FOCUS</b>			
<ul style="list-style-type: none"> <li>• Cancer &gt; Hematology &gt; Lymphoma &amp; CLL</li> <li>• Autologous &amp; Allogeneic Blood and Marrow Transplantation</li> <li>• Cancer &gt; Cancer Immunotherapy</li> </ul>			
<b>RESEARCH FOCUS</b>			
<ul style="list-style-type: none"> <li>• Development of Cancer Immunotherapy &gt; EBV-CTL in EBV-associated Lymphoma</li> <li>• Adoptive Cell Therapy following Autologous &amp; Allogeneic HSCT</li> <li>• Intentional Induction of Allogeneic Mixed chimerism for Solid Organ Transplantation</li> <li>• Combinatory Cell-Based Immune Modulation with Mesenchymal Stem Cells &amp; Regulatory Cells</li> <li>• Integration of Molecular Imaging in Translational Research</li> </ul>			
<b>ACADEMIC APPOINTMENTS</b>			
<ul style="list-style-type: none"> <li>• Professor, Hematology, Lymphoma and Myeloma Center, Hematology Hospital, Seoul St. Mary's Hospital</li> </ul>			
<b>ADMINISTRATIVE APPOINTMENTS</b>			
<ul style="list-style-type: none"> <li>• Chief Executive Officer, LucasBio Co., Ltd.</li> <li>• Director, Department of Internal Medicine, Seoul St. Mary's Hospital</li> <li>• Director of Lymphoma-Myeloma Center, Catholic Hematology Hospital</li> <li>• Director, Lymphoma and Cell Therapy Research Center, Yeouido St. Mary's Hospital</li> <li>• Director, Institute of Translational Research and Molecular Imaging</li> </ul>			
<b>PROFESSIONAL SOCIETIES &amp; MEMBERSHIPS:</b>			
President, Korean Society of Experimental Hematology Member of academic societies American Association of Cancer Research, International Society of Cell Therapy, American Society of Hematology, European Society of Hematology, Japanese Society of Hematology, Korean Medical Association, Korean Association of Internal Medicine, Korean Society of Hematology, Korean Society of Hematopoietic Stem Cell Transplantation			

## A. Professional Experience

1988 - 1995	Received Medical Doctor License (No.35974), Ministry of Health, Korea
1988 - 1989	Internship and Resident in Kangnam St. Mary Hospital, The Catholic University of Korea College of Medicine
1989 - 1992	Residency in St. Mary Hospital, The Catholic University of Korea College of Medicine
1992	Received Board Certificate of Internal Medicine (No. 3531), Korea
1992 – 1995	Served in Korean Army as physician
1995 - 1996	Fellowship of Internal medicine in St. Mary Hospital, Catholic Blood and Marrow Transplantation Center
1997	Board certified in subspecialty of Hematology, (No 697117) Korea
2001 - 2003	A scholarship research fellow of a TBRF (Tokyo Biochemical Research Foundation) postdoctoral fellowship program, Department of Molecular therapy, The Institute of Medical Science, The University of Tokyo (IMUST), Japan
1996 - 2009	Instructor, Assistant Professor, Associate Professor, Department of Hematology, The Catholic University of Korea College of Medicine
2009 - 2017	Director, Cell Therapy Center, Seoul St. Mary's Hospital
2013 - 2017	Director, Catholic Institute of Cell Therapy, The Catholic University of Korea Institute of Biomedical Industry
2014 - present	Director, Institute of Translational Research and Molecular Imaging, The Catholic University of Korea
2019- present	Director, Lymphoma and Cell Therapy Research Center, Yeouido St. Mary's Hospital
2019- present	Director, Lymphoma-Myeloma Center, Catholic Hematology Hospital
2019 - present	Director, Department of Internal Medicine, Seoul St. Mary's Hospital
2019 - present	Chief Executive Officer, LucasBio Co., Ltd.

## B. All Publications (Corresponding Author Only)

1. Min GJ, Jeon YW, Park SS, Park S, Shin SH, Yahng SA, Yoon JH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Kim HJ, Min CK, Kim DW, Lee JW, **Cho SG**. The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease. *Korean J Intern Med.* 2021 Mar;36(2):424-432. doi: 10.3904/kjim.2019.330. Epub 2020 Feb 24.
2. Hong JH, Lee HH, Jung SE, Park G, O JH, Jeon YW, Choi BO, **Cho SG**. Emerging Role of Consolidative Radiotherapy After Complete Remission Following R-CHOP Immunochemotherapy in Stage III-IV Diffuse Large B-Cell Lymphoma: A Single Institutional and Case-Matched Control Study. *Front Oncol.* 2021 Feb 22;11:578865. doi: 10.3389/fonc.2021.578865. eCollection 2021.
3. Han EJ, O JH, Jung SE, Park G, Choi BO, Jeon YW, Min GJ, **Cho SG**. FDG PET/CT Findings of Castleman Disease Assessed by Histologic Subtypes and Compared with Laboratory Findings. *Diagnostics (Basel).* 2020 Nov 24;10(12):998. doi: 10.3390/diagnostics10120998.
4. Kang HJ, Lee HH, Jung SE, Park KS, O JH, Jeon YW, Choi BO, **Cho SG**. Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. *PLoS One.* 2020 Sep 22;15(9):e0238807. doi: 10.1371/journal.pone.0238807. eCollection 2020.
5. Song Y, Lim JY, Lim T, Im KI, Kim N, Nam YS, Jeon YW, Shin JC, Ko HS, Park IY, **Cho SG**. Human mesenchymal stem cells derived from umbilical cord and bone marrow exert immunomodulatory effects in different mechanisms. *World J Stem Cells.* 2020 Sep 26;12(9):1032-1049. doi: 10.4252/wjsc.v12.i9.1032.
6. Choi KH, Lee HH, Jung SE, Park KS, O JH, Jeon YW, Choi BO, Cho SG. Analysis of the response time to involved-field radiotherapy in primary gastrointestinal low-grade B-cell lymphoma. *Radiat Oncol.*

- 2020 Aug 31;15(1):210. doi: 10.1186/s13014-020-01649-6.
7. Hong JH, Jee WH, Whang S, Jung CK, Chung YG, **Cho SG**. Differentiation of soft-tissue lymphoma from undifferentiated sarcoma: apparent diffusion coefficient histogram analysis. *Acta Radiol*. 2020 Aug 26;284185120951959. doi: 10.1177/0284185120951959. Online ahead of print.
  8. Jeon YW, O JH, Park KS, Min GJ, Park SS, Yoon JH, Eom KS, Min CK, **Cho SG**. Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP. *Br J Haematol*. 2020 Mar;188(6):860-871. doi: 10.1111/bjh.16257.
  9. Min GJ, Jeon YW, Park SS, Shin SH, Yahng SA, Yoon JH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Kim HJ, Min CK, Kim DW, Lee JW, **Cho SG**. Poor prognosis in patients with diffuse large B cell lymphomas with bone marrow involvement possessing chromosomal abnormalities, despite aggressive treatment. *Ann Hematol*. 2020 Mar;99(3):557-570. doi: 10.1007/s00277-020-03929-3.
  10. Kim N, **Cho SG**. Implications of NKG2A in EBV Reactivation and Chronic Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. *Transplantation*. 2020 Jan;104(1):e1-e2. doi: 10.1097/TP.0000000000002942.
  11. Jeon YW, Yoon S, Min GJ, Park SS, Park S, Yoon JH, Le SE, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Lee JW, **Cho SG**. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience. *Cancer Med*. 2019 Nov;8(16):6860-6870. doi: 10.1002/cam4.2565.
  12. Boo SH, O JH, Kwon SJ, Yoo IR, Kim SH, Park GS, Choi BO, Jung SE, **Cho SG**. Predictive Value of Interim and End-of-Therapy 18F-FDG PET/CT in Patients With Follicular Lymphoma. *Nucl Med Mol Imaging*. 2019 Aug;53(4):263-269. Doi: 10.1007/s13139-109-00602-0.
  13. Jeon YW, Yoon S, Min GJ, Park SS, Park S, Yoon JH, Lee SE, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Lee JW, **Cho SG**. Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma. *Ann Hematol*. 2019 May 14. doi: 10.1007/s00277-019-03714-x. [Epub ahead of print]
  14. Jeon YW, Yoon S, Min GJ, Park SS, Park S, Yoon JH, Lee SE, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Lee JW, **Cho SG**. Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. *Clin Lymphoma Myeloma Leuk*. 2019 Mar 30. pii: S2152-2650(18)31677-X. doi: 10.1016/j.clml.2019.03.023. [Epub ahead of print]
  15. Nam YS, Im KI, Kim N, Song Y, Lee JS, Jeon YW, **Cho SG**. Down-regulation of intracellular reactive oxygen species attenuates P-glycoprotein-associated chemoresistance in Epstein-Barr virus-positive NK/T-cell lymphoma. *Am J Transl Res*. 2019 Mar 15;11(3):1359-1373. eCollection 2019.
  16. Yoon JH, Min GJ, Park SS, Jeon YW, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Kim HJ, Min CK, Lee JW, **Cho SG**. Autologous hematopoietic cell transplantation using dose-reduced intravenous busulfan, melphalan, and thiotepa for high-risk or relapsed lymphomas. *Bone Marrow Transplant*. 2019 Feb;54(2):330-333.
  17. Im KI, Nam YS, Kim N, Song Y, Lee ES, Lim JY, Jeon YW, **Cho SG**. Regulation of HMGB1 release protects chemoradiotherapy-associated mucositis. *Mucosal Immunol*. 2019 Jan 15. doi: 10.1038/s41385-019-0132-x. [Epub ahead of print]
  18. Jeon YW, Lim JY, Im KI, Kim N, Nam YS, Song YJ, **Cho SG**. Enhancement of Graft-Versus-Host Disease Control Efficacy by Adoptive Transfer of Type 1 Regulatory T Cells in Bone Marrow Transplant Model. *Stem Cells Dev*. 2019 Jan 15;28(2):129-140.
  19. Jeon YW, Yang HJ, Choi BO, Jung SE, Park KS, O JH, Yang SW, **Cho SG**. Comparison of Selection and Long-term Clinical Outcomes Between Chemotherapy and Radiotherapy as Primary Therapeutic Modality for Ocular Adnexal MALT Lymphoma. *EClinicalMedicine*. 2018 Oct 17;4-5:32-42.
  20. doi: 10.1016/j.eclinm.2018.10.001. eCollection Oct-Nov 2018.

21. Kim N, Sohn HJ, Oh JH, Jeon YW, Lee HJ, Cho HI, Chung BH, Yang CW, Kim TG, **Cho SG**. Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases. *Int J Hematol*. 2018 May;107(5):596-603.
22. Kim JH, Jeon YW, Choi BO, Park G, Hong YK, Yang SW, **Cho SG**. Intracranial relapse as a solitary mass of ocular adnexal lymphoma of the mucosa-associated lymphoid tissue type. *Korean J Intern Med*. 2018 Jan;33(1):224-227.
23. Kim N, Nam YS, Im KI, Lim JY, Jeon YW, Song Y, Lee JW, **Cho SG**. Robust production of cytomegalovirus pp65-specific T cells using a fully automated IFN-g cytokine capture system. *Transfus Med Hemother*. 2018 Jan;45(1):13-22.
24. Lim JY, Im KI, Song Y, Kim N, Nam YS, Jeon YW, **Cho SG**. Third-party regulatory T cells prevent murine acute graft-versus-host disease. *Korean J Intern Med*. 2017 Oct 19. doi: 10.3904/kjim.2016.319. [Epub ahead of print]
25. Jeon YW, Kwak DH, Park SS, Yoon JH, Lee SE, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Lee JW, Min WS, **Cho SG**. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome. *Clin Lymphoma Myeloma Leuk*. 2017 Sep;17(9):595-603. doi: 10.1016/j.clml.2017.06.027.
26. Kim SY, Yang SW, Lee WS, Yang JW, Oh SY, Ahn HB, Yang DH, Park SK, Chang JH, Kim HJ, Lee MJ, **Cho SG**. Frontline treatment with chemoimmunotherapy for limited-stage ocular adnexal MALT lymphoma with adverse factors: a phase II study. *Oncotarget*. 2017 Aug 2;8(40):68583-68590. doi: 10.18632/oncotarget.19788. eCollection 2017 Sep 15.
27. Kim N, **Cho SG**. Alternative approaches to preserve MSC progenitor potency. *Blood Res*. 2017 Mar;52(1):1-2. doi: 10.5045/br.2017.52.1.1. Epub 2017 Mar 27.
28. Yoon JH, Jeon YW, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Kim HJ, Min CK, Lee JW, Min WS, **Cho SG**. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas. *Hematol Oncol*. 2017 Mar;35(1):17-24. doi: 10.1002/hon.2201. Epub 2015 Mar 18.
29. Han EJ, O JH, Yoon H, Jung SE, Park G, Choi BO, **Cho SG**. FDG PET/CT response in diffuse large B-cell lymphoma: Reader variability and association with clinical outcome. *Medicine (Baltimore)*. 2016 Sep;95(39):e4983.
30. Kim JH, Jeon YW, Choi BO, Park G, Hong YK, Yang SW, **Cho SG**. Intracranial relapse as a solitary mass of ocular adnexal lymphoma of the mucosa-associated lymphoid tissue type. *Korean J Intern Med*. 2016 Sep 7. doi: 10.3904/kjim.2015.138.
31. Jeon YW, Yoon JH, Lee SE, Eom KS, Kim YJ, Kim HJ, Lee S, Min CK, Lee JW, Min WS, **Cho SG**. Clinical manifestations of autoimmune disease-related non-Hodgkin lymphoma: a Korean single-center, retrospective clinical study. *Korean J Intern Med*. 2016 Sep;31(5):944-52. doi: 10.3904/kjim.2015.097.
32. Yoon SB, Lee IS, Lee HN, Kim E, Kim W, Lee HH, Lee BI, Choi MG, Jung SE, Choi BO, Park GS, **Cho SG**: Role of follow-up endoscopic examination in treatment response assessment for patients with gastric diffuse large b cell lymphoma. *Scandinavian journal of gastroenterology* 2016;51:1111-1117.
33. Lim JY, Im KI, Lee ES, Kim N, Nam YS, Jeon YW, **Cho SG**: Enhanced immunoregulation of mesenchymal stem cells by il-10-producing type 1 regulatory t cells in collagen-induced arthritis. *Scientific reports* 2016;6:26851.
34. Kim N, Jeon YW, Nam YS, Lim JY, Im KI, Lee ES, **Cho SG**: Therapeutic potential of low-dose il-2 in a chronic gvhd patient by in vivo expansion of regulatory t cells. *Cytokine* 2016;78:22-26.
35. Kim N, **Cho SG**: Overcoming immunoregulatory plasticity of mesenchymal stem cells for accelerated clinical applications. *International journal of hematology* 2016;103:129-137.